ArticleJapanese journal of clinical oncology2021

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.

Hiroyoshi Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.